BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Britten CM, Janetzki S, Ben-Porat L, Clay TM, Kalos M, Maecker H, Odunsi K, Pride M, Old L, Hoos A, Romero P; HLA-peptide Multimer Proficiency Panel of the CVC-CRI Immune Assay Working Group. Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium. Cancer Immunol Immunother 2009;58:1701-13. [PMID: 19259668 DOI: 10.1007/s00262-009-0681-z] [Cited by in Crossref: 55] [Cited by in F6Publishing: 57] [Article Influence: 3.9] [Reference Citation Analysis]
Number Citing Articles
1 Hoos A, Britten C. The immuno-oncology framework: Enabling a new era of cancer therapy. Oncoimmunology 2012;1:334-9. [PMID: 22737609 DOI: 10.4161/onci.19268] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 15.0] [Reference Citation Analysis]
2 Bilich T, Nelde A, Bauer J, Walz S, Roerden M, Salih HR, Weisel K, Besemer B, Marcu A, Lübke M, Schuhmacher J, Neidert MC, Rammensee HG, Stevanović S, Walz JS. Mass spectrometry-based identification of a B-cell maturation antigen-derived T-cell epitope for antigen-specific immunotherapy of multiple myeloma. Blood Cancer J 2020;10:24. [PMID: 32111817 DOI: 10.1038/s41408-020-0288-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
3 Bidmon N, Gouttefangeas C, van der Burg SH. Generation of TCR-engineered reference cell samples to control T-cell assay performance. Methods Enzymol 2020;631:195-221. [PMID: 31948547 DOI: 10.1016/bs.mie.2019.05.010] [Reference Citation Analysis]
4 Wen PY, Reardon DA, Armstrong TS, Phuphanich S, Aiken RD, Landolfi JC, Curry WT, Zhu JJ, Glantz M, Peereboom DM, Markert JM, LaRocca R, O'Rourke DM, Fink K, Kim L, Gruber M, Lesser GJ, Pan E, Kesari S, Muzikansky A, Pinilla C, Santos RG, Yu JS. A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Glioblastoma. Clin Cancer Res 2019;25:5799-807. [PMID: 31320597 DOI: 10.1158/1078-0432.CCR-19-0261] [Cited by in Crossref: 82] [Cited by in F6Publishing: 89] [Article Influence: 20.5] [Reference Citation Analysis]
5 Staats J, Divekar A, Mccoy JP, Maecker HT. Guidelines for Gating Flow Cytometry Data for Immunological Assays. Methods in Molecular Biology 2019. [DOI: 10.1007/978-1-4939-9650-6_5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
6 Bidmon N, Kind S, Welters MJP, Joseph-Pietras D, Laske K, Maurer D, Hadrup SR, Schreibelt G, Rae R, Sahin U, Gouttefangeas C, Britten CM, van der Burg SH. Development of an RNA-based kit for easy generation of TCR-engineered lymphocytes to control T-cell assay performance. J Immunol Methods 2018;458:74-82. [PMID: 29684430 DOI: 10.1016/j.jim.2018.04.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
7 Scheikl-Gatard T, Tosch C, Lemonnier F, Rooke R. Identification of new MUC1 epitopes using HLA-transgenic animals: implication for immunomonitoring. J Transl Med 2017;15:154. [PMID: 28679396 DOI: 10.1186/s12967-017-1254-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
8 Matko S, Teichert M, Tunger A, Schmitz M, Bornhauser M, Tonn T, Odendahl M. Enumeration of WT1-specific CD8+ T cells for clinical application using an MHC Streptamer based no-wash single-platform flow-cytometric assay. Cytometry A 2017;91:1001-8. [PMID: 28544366 DOI: 10.1002/cyto.a.23146] [Reference Citation Analysis]
9 Masucci GV, Cesano A, Hawtin R, Janetzki S, Zhang J, Kirsch I, Dobbin KK, Alvarez J, Robbins PB, Selvan SR, Streicher HZ, Butterfield LH, Thurin M. Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation. J Immunother Cancer 2016;4:76. [PMID: 27895917 DOI: 10.1186/s40425-016-0178-1] [Cited by in Crossref: 122] [Cited by in F6Publishing: 127] [Article Influence: 17.4] [Reference Citation Analysis]
10 Chandran PA, Laske K, Cazaly A, Rusch E, Schmid-horch B, Rammensee H, Ottensmeier CH, Gouttefangeas C. Validation of Immunomonitoring Methods for Application in Clinical Studies: The HLA-Peptide Multimer Staining Assay: VALIDATION OF THE HLA-MULTIMER STAINING ASSAY. Cytometry 2018;94:342-53. [DOI: 10.1002/cyto.b.21397] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
11 Rampling R, Peoples S, Mulholland PJ, James A, Al-Salihi O, Twelves CJ, McBain C, Jefferies S, Jackson A, Stewart W, Lindner J, Kutscher S, Hilf N, McGuigan L, Peters J, Hill K, Schoor O, Singh-Jasuja H, Halford SE, Ritchie JW. A Cancer Research UK First Time in Human Phase I Trial of IMA950 (Novel Multipeptide Therapeutic Vaccine) in Patients with Newly Diagnosed Glioblastoma. Clin Cancer Res 2016;22:4776-85. [PMID: 27225692 DOI: 10.1158/1078-0432.CCR-16-0506] [Cited by in Crossref: 88] [Cited by in F6Publishing: 94] [Article Influence: 12.6] [Reference Citation Analysis]
12 Fecci PE, Riccione K, Dunn GP, Reap E, Vlahovic G, Congdon K, Sampson JH. Immunotherapy for gliomas. The Duke Glioma Handbook 2016. [DOI: 10.1017/cbo9781107588721.006] [Reference Citation Analysis]
13 Mandruzzato S, Brandau S, Britten CM, Bronte V, Damuzzo V, Gouttefangeas C, Maurer D, Ottensmeier C, van der Burg SH, Welters MJ, Walter S. Toward harmonized phenotyping of human myeloid-derived suppressor cells by flow cytometry: results from an interim study. Cancer Immunol Immunother 2016;65:161-9. [PMID: 26728481 DOI: 10.1007/s00262-015-1782-5] [Cited by in Crossref: 144] [Cited by in F6Publishing: 139] [Article Influence: 20.6] [Reference Citation Analysis]
14 Higuchi Y, Koya T, Yuzawa M, Yamaoka N, Mizuno Y, Yoshizawa K, Hirabayashi K, Kobayashi T, Sano K, Shimodaira S. Enzyme-Linked Immunosorbent Spot Assay for the Detection of Wilms' Tumor 1-Specific T Cells Induced by Dendritic Cell Vaccination. Biomedicines 2015;3:304-15. [PMID: 28536414 DOI: 10.3390/biomedicines3040304] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
15 Butterfield LH. Cancer vaccines. BMJ 2015;350:h988. [PMID: 25904595 DOI: 10.1136/bmj.h988] [Cited by in Crossref: 167] [Cited by in F6Publishing: 166] [Article Influence: 20.9] [Reference Citation Analysis]
16 Gouttefangeas C, Chan C, Attig S, Køllgaard TT, Rammensee HG, Stevanović S, Wernet D, thor Straten P, Welters MJ, Ottensmeier C, van der Burg SH, Britten CM. Data analysis as a source of variability of the HLA-peptide multimer assay: from manual gating to automated recognition of cell clusters. Cancer Immunol Immunother 2015;64:585-98. [PMID: 25854580 DOI: 10.1007/s00262-014-1649-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
17 Baxevanis CN, Anastasopoulou EA, Voutsas IF, Papamichail M, Perez SA. Immune biomarkers: how well do they serve prognosis in human cancers? Expert Rev Mol Diagn 2015;15:49-59. [PMID: 25345403 DOI: 10.1586/14737159.2015.965684] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
18 Hadrup SR, Maurer D, Laske K, Frøsig TM, Andersen SR, Britten CM, van der Burg SH, Walter S, Gouttefangeas C. Cryopreservation of MHC multimers: Recommendations for quality assurance in detection of antigen specific T cells. Cytometry A 2015;87:37-48. [PMID: 25297339 DOI: 10.1002/cyto.a.22575] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
19 Chudley L, McCann KJ, Coleman A, Cazaly AM, Bidmon N, Britten CM, van der Burg SH, Gouttefangeas C, Jandus C, Laske K, Maurer D, Romero P, Schröder H, Stynenbosch LF, Walter S, Welters MJ, Ottensmeier CH. Harmonisation of short-term in vitro culture for the expansion of antigen-specific CD8(+) T cells with detection by ELISPOT and HLA-multimer staining. Cancer Immunol Immunother 2014;63:1199-211. [PMID: 25134947 DOI: 10.1007/s00262-014-1593-0] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
20 Hoos A. Developing Cancer Immunotherapies as Drugs: Setting the Stage Through Methodological Progress. Cancer Immunotherapy Meets Oncology 2014. [DOI: 10.1007/978-3-319-05104-8_6] [Reference Citation Analysis]
21 van der Burg SH, Walter S, Janetzki S, Britten CM, Galon J, Welters MJP, Gouttefangeas C. Immunoguiding, the Final Frontier in the Immunotherapy of Cancer. Cancer Immunotherapy Meets Oncology 2014. [DOI: 10.1007/978-3-319-05104-8_5] [Reference Citation Analysis]
22 Borchers S, Ogonek J, Varanasi PR, Tischer S, Bremm M, Eiz-Vesper B, Koehl U, Weissinger EM. Multimer monitoring of CMV-specific T cells in research and in clinical applications. Diagn Microbiol Infect Dis 2014;78:201-12. [PMID: 24331953 DOI: 10.1016/j.diagmicrobio.2013.11.007] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
23 Macchia I, Urbani F, Proietti E. Immune monitoring in cancer vaccine clinical trials: critical issues of functional flow cytometry-based assays. Biomed Res Int 2013;2013:726239. [PMID: 24195078 DOI: 10.1155/2013/726239] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.6] [Reference Citation Analysis]
24 Britten CM, Walter S, Janetzki S. Immunological Monitoring to Rationally Guide AAV Gene Therapy. Front Immunol 2013;4:273. [PMID: 24062741 DOI: 10.3389/fimmu.2013.00273] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
25 Welters MJ, van der Burg SH. Comprehensive Immunomonitoring to Guide the Development of Immunotherapeutic Products for Cancer. Cancer Immunotherapy. Elsevier; 2013. pp. 241-58. [DOI: 10.1016/b978-0-12-394296-8.00016-6] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
26 Hoos A. Evolution of end points for cancer immunotherapy trials. Annals of Oncology 2012;23:viii47-52. [DOI: 10.1093/annonc/mds263] [Cited by in Crossref: 74] [Cited by in F6Publishing: 82] [Article Influence: 6.7] [Reference Citation Analysis]
27 Lasso P, Mesa D, Bolaños N, Cuéllar A, Guzmán F, Cucunuba Z, Rosas F, Velasco V, Thomas MC, López MC, González JM, Puerta CJ. Chagasic patients are able to respond against a viral antigen from influenza virus. BMC Infect Dis 2012;12:198. [PMID: 22920436 DOI: 10.1186/1471-2334-12-198] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
28 Janetzki S, Romero P, Roederer M, Bolton DL, Jandus C. Immune Monitoring Design within the Developmental Pipeline for an Immunotherapeutic or Preventive Vaccine. Vaccinology 2012. [DOI: 10.1002/9781118345313.ch28] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
29 van der Burg SH, Kalos M, Gouttefangeas C, Janetzki S, Ottensmeier C, Welters MJ, Romero P, Britten CM, Hoos A. Harmonization of immune biomarker assays for clinical studies. Sci Transl Med 2011;3:108ps44. [PMID: 22072636 DOI: 10.1126/scitranslmed.3002785] [Cited by in Crossref: 65] [Cited by in F6Publishing: 77] [Article Influence: 5.9] [Reference Citation Analysis]
30 Janetzki S, Britten CM. The Impact of Harmonization on ELISPOT Assay Performance. Methods in Molecular Biology 2012. [DOI: 10.1007/978-1-61779-325-7_2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 2.9] [Reference Citation Analysis]
31 Fox BA, Schendel DJ, Butterfield LH, Aamdal S, Allison JP, Ascierto PA, Atkins MB, Bartunkova J, Bergmann L, Berinstein N, Bonorino CC, Borden E, Bramson JL, Britten CM, Cao X, Carson WE, Chang AE, Characiejus D, Choudhury AR, Coukos G, de Gruijl T, Dillman RO, Dolstra H, Dranoff G, Durrant LG, Finke JH, Galon J, Gollob JA, Gouttefangeas C, Grizzi F, Guida M, Håkansson L, Hege K, Herberman RB, Hodi FS, Hoos A, Huber C, Hwu P, Imai K, Jaffee EM, Janetzki S, June CH, Kalinski P, Kaufman HL, Kawakami K, Kawakami Y, Keilholtz U, Khleif SN, Kiessling R, Kotlan B, Kroemer G, Lapointe R, Levitsky HI, Lotze MT, Maccalli C, Maio M, Marschner JP, Mastrangelo MJ, Masucci G, Melero I, Melief C, Murphy WJ, Nelson B, Nicolini A, Nishimura MI, Odunsi K, Ohashi PS, O'Donnell-Tormey J, Old LJ, Ottensmeier C, Papamichail M, Parmiani G, Pawelec G, Proietti E, Qin S, Rees R, Ribas A, Ridolfi R, Ritter G, Rivoltini L, Romero PJ, Salem ML, Scheper RJ, Seliger B, Sharma P, Shiku H, Singh-Jasuja H, Song W, Straten PT, Tahara H, Tian Z, van Der Burg SH, von Hoegen P, Wang E, Welters MJ, Winter H, Withington T, Wolchok JD, Xiao W, Zitvogel L, Zwierzina H, Marincola FM, Gajewski TF, Wigginton JM, Disis ML. Defining the critical hurdles in cancer immunotherapy. J Transl Med 2011;9:214. [PMID: 22168571 DOI: 10.1186/1479-5876-9-214] [Cited by in Crossref: 123] [Cited by in F6Publishing: 131] [Article Influence: 10.3] [Reference Citation Analysis]
32 Hoos A, Britten CM, Huber C, O'Donnell-Tormey J. A methodological framework to enhance the clinical success of cancer immunotherapy. Nat Biotechnol 2011;29:867-70. [PMID: 21997622 DOI: 10.1038/nbt.2000] [Cited by in Crossref: 49] [Cited by in F6Publishing: 53] [Article Influence: 4.1] [Reference Citation Analysis]
33 Speetjens FM, Zeestraten EC, Kuppen PJ, Melief CJ, van der Burg SH. Colorectal cancer vaccines in clinical trials. Expert Rev Vaccines 2011;10:899-921. [PMID: 21692708 DOI: 10.1586/erv.11.63] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
34 Musselli C, Isakov L, Wentworth K. Emerging clinical trial design concepts for therapeutic cancer vaccines. Cancer Vaccines: From Research to Clinical Practice 2011. [DOI: 10.3109/9781841848303.011] [Reference Citation Analysis]
35 Britten CM, Janetzki S, Gouttefangeas C, Welters MJP, Kalos M, Ottensmeier C, Hoos A, van der Burg SH. T-cell immune monitoring assays to guide the development of new cancer vaccines. Cancer Vaccines: From Research to Clinical Practice 2011. [DOI: 10.3109/9781841848303.012] [Reference Citation Analysis]
36 Davis MM, Altman JD, Newell EW. Interrogating the repertoire: broadening the scope of peptide-MHC multimer analysis. Nat Rev Immunol 2011;11:551-8. [PMID: 21760610 DOI: 10.1038/nri3020] [Cited by in Crossref: 87] [Cited by in F6Publishing: 91] [Article Influence: 7.3] [Reference Citation Analysis]
37 Attig S, Price L, Janetzki S, Kalos M, Pride M, McNeil L, Clay T, Yuan J, Odunsi K, Hoos A, Romero P, Britten CM; CRI-CIC Assay Working Group. A critical assessment for the value of markers to gate-out undesired events in HLA-peptide multimer staining protocols. J Transl Med 2011;9:108. [PMID: 21745365 DOI: 10.1186/1479-5876-9-108] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 1.8] [Reference Citation Analysis]
38 Butterfield LH, Palucka AK, Britten CM, Dhodapkar MV, Håkansson L, Janetzki S, Kawakami Y, Kleen TO, Lee PP, Maccalli C, Maecker HT, Maino VC, Maio M, Malyguine A, Masucci G, Pawelec G, Potter DM, Rivoltini L, Salazar LG, Schendel DJ, Slingluff CL Jr, Song W, Stroncek DF, Tahara H, Thurin M, Trinchieri G, van Der Burg SH, Whiteside TL, Wigginton JM, Marincola F, Khleif S, Fox BA, Disis ML. Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. Clin Cancer Res 2011;17:3064-76. [PMID: 21558394 DOI: 10.1158/1078-0432.CCR-10-2234] [Cited by in Crossref: 87] [Cited by in F6Publishing: 96] [Article Influence: 7.3] [Reference Citation Analysis]
39 Olson WC, Smolkin ME, Farris EM, Fink RJ, Czarkowski AR, Fink JH, Chianese-Bullock KA, Slingluff CL Jr. Shipping blood to a central laboratory in multicenter clinical trials: effect of ambient temperature on specimen temperature, and effects of temperature on mononuclear cell yield, viability and immunologic function. J Transl Med 2011;9:26. [PMID: 21385453 DOI: 10.1186/1479-5876-9-26] [Cited by in Crossref: 60] [Cited by in F6Publishing: 62] [Article Influence: 5.0] [Reference Citation Analysis]
40 Chan C, Lin L, Frelinger J, Hérbert V, Gagnon D, Landry C, Sékaly RP, Enzor J, Staats J, Weinhold KJ, Jaimes M, West M. Optimization of a highly standardized carboxyfluorescein succinimidyl ester flow cytometry panel and gating strategy design using discriminative information measure evaluation. Cytometry A 2010;77:1126-36. [PMID: 21053294 DOI: 10.1002/cyto.a.20987] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
41 Perrin H, Canderan G, Sékaly RP, Trautmann L. New approaches to design HIV-1 T-cell vaccines. Curr Opin HIV AIDS 2010;5:368-76. [PMID: 20978376 DOI: 10.1097/COH.0b013e32833d2cc0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
42 Gilewski T. Targeting the Immune System as a Therapeutic Strategy for Patients with Breast Cancer. Curr Breast Cancer Rep 2010;2:214-221. [DOI: 10.1007/s12609-010-0029-x] [Reference Citation Analysis]
43 Britten CM, Janetzki S, van der Burg SH, Huber C, Kalos M, Levitsky HI, Maecker HT, Melief CJ, O'Donnell-Tormey J, Odunsi K, Old LJ, Pawelec G, Roep BO, Romero P, Hoos A, Davis MM. Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond. Cancer Immunol Immunother 2011;60:15-22. [PMID: 21080166 DOI: 10.1007/s00262-010-0940-z] [Cited by in Crossref: 51] [Cited by in F6Publishing: 40] [Article Influence: 3.9] [Reference Citation Analysis]
44 Soliman H. Developing an effective breast cancer vaccine. Cancer Control 2010;17:183-90. [PMID: 20664516 DOI: 10.1177/107327481001700307] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 2.0] [Reference Citation Analysis]
45 Hoos A, Eggermont AM, Janetzki S, Hodi FS, Ibrahim R, Anderson A, Humphrey R, Blumenstein B, Old L, Wolchok J. Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst 2010;102:1388-97. [PMID: 20826737 DOI: 10.1093/jnci/djq310] [Cited by in Crossref: 413] [Cited by in F6Publishing: 439] [Article Influence: 31.8] [Reference Citation Analysis]
46 Jaimes MC, Maecker HT, Yan M, Maino VC, Hanley MB, Greer A, Darden JM, D'Souza MP. Quality assurance of intracellular cytokine staining assays: analysis of multiple rounds of proficiency testing. J Immunol Methods 2011;363:143-57. [PMID: 20727897 DOI: 10.1016/j.jim.2010.08.004] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 2.4] [Reference Citation Analysis]
47 Frelinger J, Ottinger J, Gouttefangeas C, Chan C. Modeling flow cytometry data for cancer vaccine immune monitoring. Cancer Immunol Immunother 2010;59:1435-41. [PMID: 20563720 DOI: 10.1007/s00262-010-0883-4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
48 Heery CR, Madan RA. Modern immunotherapy for the treatment of prostate cancer. Drug Discovery Today: Therapeutic Strategies 2010;7:37-42. [DOI: 10.1016/j.ddstr.2011.02.003] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
49 Madore DV, Meade BD, Rubin F, Deal C, Lynn F; Meeting Contributors. Utilization of serologic assays to support efficacy of vaccines in nonclinical and clinical trials: meeting at the crossroads. Vaccine 2010;28:4539-47. [PMID: 20470795 DOI: 10.1016/j.vaccine.2010.04.094] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 2.2] [Reference Citation Analysis]
50 Parida SK, Magalhaes I, Dubois P, Janetzki S. Training in immunology of relevance to global health issues in resource poor settings. Eur J Immunol 2010;40:1228-31. [DOI: 10.1002/eji.201090022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
51 Speiser DE, Romero P. Molecularly defined vaccines for cancer immunotherapy, and protective T cell immunity. Semin Immunol. 2010;22:144-154. [PMID: 20413326 DOI: 10.1016/j.smim.2010.03.004] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 2.6] [Reference Citation Analysis]
52 Kalos M. An integrative paradigm to impart quality to correlative science. J Transl Med 2010;8:26. [PMID: 20233418 DOI: 10.1186/1479-5876-8-26] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 1.9] [Reference Citation Analysis]
53 Mander A, Gouttefangeas C, Ottensmeier C, Welters MJ, Low L, van der Burg SH, Britten CM. Serum is not required for ex vivo IFN-gamma ELISPOT: a collaborative study of different protocols from the European CIMT Immunoguiding Program. Cancer Immunol Immunother 2010;59:619-27. [PMID: 20052465 DOI: 10.1007/s00262-009-0814-4] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.0] [Reference Citation Analysis]
54 Axelsson-Robertson R, Weichold F, Sizemore D, Wulf M, Skeiky YA, Sadoff J, Maeurer MJ. Extensive major histocompatibility complex class I binding promiscuity for Mycobacterium tuberculosis TB10.4 peptides and immune dominance of human leucocyte antigen (HLA)-B*0702 and HLA-B*0801 alleles in TB10.4 CD8 T-cell responses. Immunology 2010;129:496-505. [PMID: 20002212 DOI: 10.1111/j.1365-2567.2009.03201.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 38] [Article Influence: 2.4] [Reference Citation Analysis]
55 Janetzki S, Price L, Britten CM, van der Burg SH, Caterini J, Currier JR, Ferrari G, Gouttefangeas C, Hayes P, Kaempgen E, Lennerz V, Nihlmark K, Souza V, Hoos A. Performance of serum-supplemented and serum-free media in IFNgamma Elispot Assays for human T cells. Cancer Immunol Immunother 2010;59:609-18. [PMID: 19894047 DOI: 10.1007/s00262-009-0788-2] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 2.7] [Reference Citation Analysis]
56 Casalegno-Garduño R, Schmitt A, Yao J, Wang X, Xu X, Freund M, Schmitt M. Multimer technologies for detection and adoptive transfer of antigen-specific T cells. Cancer Immunol Immunother 2010;59:195-202. [PMID: 19847424 DOI: 10.1007/s00262-009-0778-4] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 2.6] [Reference Citation Analysis]